Drug Trial Radar · NCT05668741
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Feb 27, 2023
Primary completion
Apr 21, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- Moderna, Inc
- First posted
- Dec 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Conditions
- Cystic Fibrosis
Interventions
VX-522 mRNA therapyDrug
Oral inhalation using nebulizer.
IVADrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Week 8 [SAD and MAD]
Locations
26 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Child Health Research Unit
Birmingham, Alabama
Memorial Health Services on behalf of Long Beach Memorial Medical Center d/b/a Miller Children's Hospital Long Beach
Long Beach, California
Stanford University - Palo Alto - Pulmonology
Palo Alto, California
National Jewish Health
Denver, Colorado
Clinical & Translational Science Unit (CTSU) - Pulmonology
Kansas City, Kansas
PAREXEL International - Baltimore
Baltimore, Maryland
The Johns Hopkins University - Johns Hopkins Hospital - Pulmonology
Baltimore, Maryland
MGH - MGfC Pediatric Cystic Fibrosis Center
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
University of Minnesota -Pulmonology
Minneapolis, Minnesota
St. Louis Children's Hospital - Pulmonology
St Louis, Missouri
UC Health Holmes Hospital
Cincinnati, Ohio
Medical University of South Carolina - Pulmonology
Charleston, South Carolina
University of Utah Hospital - Pulmonology
Salt Lake City, Utah
The Alfred Hospital - Pulmonology
Melbourne, Australia
Universitair Ziekenhuis Gent
Ghent, Belgium
University of Calgary Medical Clinic of the Foothills Medical Centre
Calgary, Canada
IUCPQ Pavillon Recherche U-1771
Québec, Canada
Ruhrlandklinik
Essen, Germany
Karolinska University Hospital - Pulmonology
Stockholm, Sweden
Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom
Queen Elizabeth University Hospital - Pulmonology
Glasgow, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Wythenshawe Hospital - OPD
Manchester, United Kingdom
All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough
Penarth, United Kingdom
University Hospital Southampton NHS Fountion - Southampton General Hospital
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.